Needham & Company Maintains a 'Hold' on ISIS Pharmaceuticals (ISIS); Strong Focus on Mipomersen Next Steps by Genzyme, Steady Progress of Early-Stage Pipeline
Tweet Send to a Friend
Needham & Company maintains a 'Hold' on ISIS Pharmaceuticals (NASDAQ: ISIS).
Needham analyst says, "Yesterday, ISIS reviewed 4Q10 results and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "Yesterday, ISIS reviewed 4Q10 results and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
